Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule
Top Cited Papers
- 1 May 2009
- journal article
- review article
- Published by Springer Nature in Nature Reviews Microbiology
- Vol. 7 (5) , 393-400
- https://doi.org/10.1038/nrmicro2129
Abstract
Ebola virus infection is a highly lethal disease for which there are no effective therapeutic or preventive treatments. Several vaccines have provided immune protection in laboratory animals, but because outbreaks occur unpredictably and sporadically, vaccine efficacy cannot be proven in human trials, which is required for traditional regulatory approval. The Food and Drug Administration has introduced the 'animal rule', to allow laboratory animal data to be used to show efficacy when human trials are not logistically feasible. In this Review, we describe immune correlates of vaccine protection against Ebola virus in animals. This research provides a basis for bridging the gap from basic research to human vaccine responses in support of the licensing of vaccines through the animal rule.Keywords
This publication has 44 references indexed in Scilit:
- Vaccines: Correlates of Vaccine‐Induced ImmunityClinical Infectious Diseases, 2008
- Ebola Virus‐Like Particle–Based Vaccine Protects Nonhuman Primates against Lethal Ebola Virus ChallengeThe Journal of Infectious Diseases, 2007
- Induction of Humoral and CD8+ T Cell Responses Are Required for Protection against Lethal Ebola Virus InfectionThe Journal of Immunology, 2005
- Persistent Infection with Ebola Virus under Conditions of Partial ImmunityJournal of Virology, 2004
- Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against Lethal Ebola Virus Infection without Complete Inhibition of Viral ReplicationJournal of Virology, 2001
- Development of a preventive vaccine for Ebola virus infection in primatesNature, 2000
- Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virusVaccine, 2000
- Human asymptomatic Ebola infection and strong inflammatory responseThe Lancet, 2000
- Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 + LymphocytesScience, 1999
- Markedly Elevated Levels of Interferon (IFN)‐σ, IFN‐α, Interleukin (IL)‐2, IL‐10, and Tumor Necrosis Factor‐α Associated with Fatal Ebola Virus InfectionThe Journal of Infectious Diseases, 1999